Detalhe da pesquisa
1.
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Ann Oncol
; 35(1): 66-76, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37866811
2.
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.
Ann Oncol
; 34(10): 907-919, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37467930
3.
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.
Ann Oncol
; 34(2): 173-185, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36414192
4.
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.
Ann Oncol
; 33(1): 67-79, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34562610
5.
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).
Ann Oncol
; 33(6): 602-615, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35263633
6.
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.
Ann Oncol
; 33(1): 57-66, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34624497
7.
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
Ann Oncol
; 32(9): 1101-1110, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34089836
8.
Small cell lung cancer: a slightly less orphan disease after immunotherapy.
Ann Oncol
; 32(6): 698-709, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33737119
9.
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
Ann Oncol
; 32(7): 881-895, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33894335
10.
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer.
Ann Oncol
; 32(12): 1597-1607, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34487855
11.
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331â.
Ann Oncol
; 32(5): 631-641, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539946
12.
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.
Ann Oncol
; 31(2): 310-317, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31959349
13.
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.
Ann Oncol
; 30(6): 884-896, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30912805
14.
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ann Oncol
; 34(4): 358-376, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36669645
15.
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ann Oncol
; 34(4): 339-357, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36872130
16.
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.
Ann Oncol
; 29(7): 1548-1553, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29767677
17.
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
Ann Oncol
; 29(8): 1701-1709, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29905778
18.
[Updated Recommendation for Treatment of Metastatic Non-Small Cell Lung Cancer]. / Aktualisierte Therapieempfehlung metastasiertes nicht kleinzelliges Lungenkarzinom.
Pneumologie
; 72(2): 138-154, 2018 Feb.
Artigo
em Alemão
| MEDLINE | ID: mdl-29270953
19.
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upâ.
Ann Oncol
; 33(2): 129-142, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34861373
20.
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66].
Ann Oncol
; 33(4): 454, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35086737